Carteolol/latanoprost

Drug Profile

Carteolol/latanoprost

Alternative Names: Carteolol hydrochloride/latanoprost; Mikeluna; OPC-1085EL

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Prostaglandins; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Glaucoma; Ocular hypertension

Most Recent Events

  • 30 Mar 2018 Otsuka Pharmaceutical suspends a clinical trial for Glaucoma in Japan (UMIN000030288)
  • 22 Nov 2017 Otsuka Pharmaceutical initiates enrolment in a trial for Glaucoma in Japan (UMIN000030288)
  • 11 Jan 2017 Inouye Eye Hospital initiates enrolment in a clinical trial for Glaucoma or Ocular hypertension in Japan (UMIN000026224)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top